Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Citius Pharmaceuticals Inc CTXR

Healthcare Biotechnology
Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company’s late-stage pipeline includes Mino-Lok, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream... see more

Current News (NDAQ:CTXR)

Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules

PR Newswire 2 days ago

Citius Oncology Expands LYMPHIR(TM) Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim

PR Newswire 7 days ago

Citius Oncology Announces U.S. Commercial Launch of LYMPHIR(TM), a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL)

PR Newswire 10 days ago

Citius Oncology to Advance Commercial Launch of LYMPHIR(TM) with Verix AI Integration

PR Newswire November 21, 2025

Citius Pharmaceuticals Announces the Closing of Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules

PR Newswire October 21, 2025

Citius Pharmaceuticals Announces a Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules

PR Newswire October 21, 2025

Citius Oncology Signs U.S. Distribution Agreement with McKesson to Support LYMPHIR(TM) Commercial Launch

PR Newswire October 20, 2025

Citius Pharmaceuticals and Citius Oncology to Participate in Upcoming October 2025 Conferences

PR Newswire October 17, 2025

Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to Support Planned Q4 2025 Launch of LYMPHIR(TM)

PR Newswire October 16, 2025
View More News ››

Opinion & Analysis (NDAQ:CTXR)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:CTXR)

Big news out today for CTXR

https://youtu.be/tU1AzxFwptw?si=cOPKMeHbzN7wkKVX
BryceCanada - November 11, 2024

New video out on CTXR

https://youtu.be/W4lOTWn3uRY?si=_KnuRrHt8WGledKD
BryceCanada - September 23, 2024

New coverage out on CTXR

https://youtu.be/5rfNA18dGZM?si=JWS4rAcKdq-RrQJh
BryceCanada - July 16, 2024

new CTXR research report - great read!

https://marketresearchrepository.com/cancer-breakthrough-of-the-decade/?utm_source=mcnalliemoney+&utm_medium=influencer&utm...
BryceCanada - May 3, 2022

Excellent YT analysis on Citius Pharmaceuticals!

https://youtu.be/hRHnqSPnhdU
BryceCanada - May 3, 2022

RE:Grab hold!

I like the speed CTXR is rolling at, especially when the overall market is down. Sure $5-$7 in sight.
Adwari - June 15, 2021
View more Bullboard ››

AJN Resources Inc.

AJN Resources Inc.

AJN Resources Inc. is a Canada-based junior exploration company and is engaged in the exploration and evaluation of mineral ...
View More »